Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors

Journal of Neuroscience

Volumn 22, Issue 3, 2002, Pages 1054-1062

  Fredduzzi, Silva ^a   Moratalla, Rosario ^b   Monopoli, Angela ^b   Cuellar, Beatriz ^b   Xu, Kui ^c   Ongini, Ennio ^c   Impagnatiello, Francesco ^b   Schwarzschild, Michael A ^a   Chen, Jiang Fan ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b San Raffaele Science Park   (Italy)

^c INSTITUTO CAJAL   (Spain)

Author keywords

A2A adenosine receptor; Behavioral sensitization; Dynorphin; Dyskinesia; L DOPA; Parkinson's disease

Indexed keywords

ADENOSINE A2A RECEPTOR; DOPAMINE RECEPTOR; DYNORPHIN; LEVODOPA; MESSENGER RNA; OXIDOPAMINE;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DYSKINESIA; KNOCKOUT MOUSE; LONG TERM CARE; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; STRIATONIGRAL DEGENERATION; WILD TYPE;

EID: 0036470494     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-03-01054.2002     Document Type: Article

References (73)

1. Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease
2. Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: Changes in DARPP-32 phosphorylation
3. DOPA-induced "peak dose" dyskinesia: Clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys
4. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats
5. Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
6. Levodopa-induced dyskinesias: A pathological form of striatal synaptic plasticity?
7. Chronic L-DOPA treatment in the unilateral 6-OHDA rat: Evidence for behavioral sensitization and biochemical tolerance
8. Neuropeptide messenger RNA expression in the 6-hydroxydopamine lesioned rat striatum reinnervated by fetal dopaminergic transplants: Differential effects of the grafts on preproenkephalin, preprotachykinin, and prodynorphin messenger RNA levels
9. L-DOPA-induced dyskinesia in the rat is associated with striatal over-expression of prodynorphin and glutamic acid decarboxylase mRNA
10. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine
11. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications
12. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice
13. 2A adenosine receptors
14. 2A adenosine receptors
15. 2A adenosine receptor inactivation in a model of Parkinson's disease
16. Sequence and expression of the rat prodynorphin gene
17. 2A receptors
18. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease
19. 2A receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice
20. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats
21. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia
22. Molecular cloning of the rat A2 adenosine receptor: Selective coexpression with D2 dopamine receptors in rat striatum
23. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use
24. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
25. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: A new hypothesis
26. 2A receptor antagonist in MPTP-treated monkeys
27. 2A receptor antagonist
28. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesia in Parkinson's disease
29. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-DOPA-induced dyskinesia
30. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
31. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum
32. Adenosine receptors in neurological disorders
33. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates
34. 2A receptor antagonist
35. 2A receptor agonists and antagonists
36. Adenosine A2a antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
37. 2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys
38. 2A receptor-mediated modulation of striatal GABA and ACh release
39. 2A receptor-mediated modulation of striatal acetylcholine release in vivo
40. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
41. Dopamine receptor gene expression by enkephalin neurons in rat forebrain
42. Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat
43. Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms
44. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats
45. Opposing actions of adenosine A2a receptor and dopamine D2 receptor activation on GABA release in the basal ganglia: Evidence for an A2aR/D2R interaction in globus pallidus
46. 2A receptors by SCH58261 results in neuroprotective effects in cerebral ischemia in rats
47. Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal
48. Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor
49. Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning
50. The selective A2a agonist CGS21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex
51. Levodopa motor complication in Parkinson's disease
52. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum
53. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants
54. 2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats
55. Coadminstration of (-)-OSU6162 with L-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions
56. Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats
57. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats
58. 2A receptor antagonists as new agents for the treatment of Parkinson's disease
59. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis
60. 2A receptors
61. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study
62. Adenosine A2 receptor-mediated excitatory actions on the nervous system
63. 2A receptors in the expression and development of methamphetamine-induced sensitization
64. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice
65. 2A receptors
66. 2A receptors
67. Does the noncompetitive NMDA receptor antagonist dizocilpine (MK801) really block behavioural sensitization associated with repeated drug administration?
68. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies
69. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants
70. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats
71. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release